Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Accenture
Daiichi Sankyo
Chinese Patent Office
US Army
Express Scripts
Cantor Fitzgerald
AstraZeneca
Fuji

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201914

« Back to Dashboard

NDA 201914 describes RIZATRIPTAN BENZOATE, which is a drug marketed by Apotex Inc, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Mylan Pharms Inc, Natco Pharma Ltd, Panacea Biotec Ltd, Sandoz, Unichem Labs Ltd, Alkem Labs Ltd, Cipla Ltd, Eci Pharms Llc, Emcure Pharms Ltd, Glenmark Generics, Invagen Pharms, and Teva Pharms, and is included in twenty-five NDAs. It is available from twenty-five suppliers. Additional details are available on the RIZATRIPTAN BENZOATE profile page.

The generic ingredient in RIZATRIPTAN BENZOATE is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.
Summary for 201914
Tradename:RIZATRIPTAN BENZOATE
Applicant:Glenmark Pharms Ltd
Ingredient:rizatriptan benzoate
Patents:0
Therapeutic Class:Antimigraine Agents
Pharmacology for NDA: 201914
Suppliers and Packaging for NDA: 201914
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 201914 ANDA Glenmark Pharmaceuticals Inc., USA 68462-467 68462-467-06 6 BOX in 1 CARTON (68462-467-06) > 3 POUCH in 1 BOX (68462-467-46) > 1 BLISTER PACK in 1 POUCH > 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 201914 ANDA Glenmark Pharmaceuticals Inc., USA 68462-467 68462-467-74 4 BOX in 1 CARTON (68462-467-74) > 3 POUCH in 1 BOX > 1 BLISTER PACK in 1 POUCH > 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 5MG BASE
Approval Date:Jul 1, 2013TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 10MG BASE
Approval Date:Jul 1, 2013TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Fish and Richardson
Daiichi Sankyo
Novartis
Citi
McKesson
Chubb
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot